Stocks:
5,472
ETFs:
2,400
Exchanges:
11
Market Cap:
$58.99T
24h Vol:
$9.85B
Dominance:
MSFT:5.13%
Stocklytics Platform
BETA
Instrument logo  GILD

Gilead Sciences Inc

GILD
73 / 100
S&P500
$73.02arrow_drop_up0.09%$0.07

Performance History

Stocklytics logo
Key Stats
Open$73.50
Prev. Close$73.55
EPS4.5
Dividend$3.00
Next Earnings DateJun 27, 2024
Dividend Yield %4.19%
Market Cap$90.89B
PE Ratio16.21
LOWHIGH
Day Range72.84
73.89
52 Week Range71.37
87.87
Ratios
P/B Ratio4.03
Revenue$27.11B
Operating M. %34.51%
Earnings$5.87B
Earnings Growth %28.69%
EBITDA Margin %46.34%
ROE %25.54%
EPS4.5

Score Breakdown

73vs 53. Market Avg.

All Score 73 / 100 is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

GILDMARKET
Value5039
Quality6140
Ownership3819
Growth7246
Dividends5437
check_circle

Gilead Sciences Inc's Price growth average in the last 3 years of 7.74% is great compared to market average of 6.83%. This indicates GILD could be a good value stock.

Financial Forecast

AI Price Prediction

line chart placeholder

Analyst Ratings

Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

PRICE$771.91
24H (%)arrow_drop_up0.30%
24H ($)$2.38
MARKET CAP$733.45B
PRICE$525.32
24H (%)arrow_drop_down-0.36%
24H ($)-$1.91
MARKET CAP$485.88B
PRICE$160.78
24H (%)arrow_drop_down-0.64%
24H ($)-$1.05
MARKET CAP$387.30B
PRICE$128.84
24H (%)arrow_drop_down-0.47%
24H ($)-$0.61
MARKET CAP$326.48B

About Gilead Sciences Inc (GILD)

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Merck & Co, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.

Sector
Healthcare
Industry
Drug Manufacturers—General
CEO
Mr. Daniel P. O'Day
Headquarters
Foster City
Employees
17000
Exchange
NASDAQ
add Gilead Sciences Inc to watchlist

Keep an eye on Gilead Sciences Inc

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
question_mark
What is Gilead Sciences Inc's (GILD) price per share?

The current price per share for Gilead Sciences Inc (GILD) is $72.95. The stock has seen a price change of -$0.6 recently, indicating a -0.82% change. This reflects the stock's recent market performance and investor sentiment.

question_mark
What is the 52-week high and low for Gilead Sciences Inc (GILD)?

For Gilead Sciences Inc (GILD), the 52-week high is $87.87, which is 20.45% from the current price. The 52-week low is $71.37, the current price is 2.21% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

question_mark
Is Gilead Sciences Inc (GILD) a growth stock?

Gilead Sciences Inc (GILD) has shown an average price growth of 7.74% over the past three years. It has received a score of 69 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Gilead Sciences Inc as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

question_mark
What is Gilead Sciences Inc (GILD) stock price performance year to date (YTD)?

As of the latest data, Gilead Sciences Inc (GILD) has a year-to-date price change of -12.38%. Over the past month, the stock has experienced a price change of -7.79%. Over the last three months, the change has been -2.66%. Looking at a longer horizon, the five-year price change stands at 11.26%.

question_mark
Is Gilead Sciences Inc (GILD) a profitable company?

Gilead Sciences Inc (GILD) has a net income of $5.88B, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 100% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 34.51% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $27.12B, although specific revenue growth data is currently not available. The gross profit is $27.12B. Operating income is noted at $7.6B. Furthermore, the EBITDA is $12.5B.

question_mark
What is the market capitalization of Gilead Sciences Inc (GILD)?

Gilead Sciences Inc (GILD) has a market capitalization of $90.9B. The average daily trading volume is 7.41M, indicating the stock's liquidity and investor engagement.

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Approach investments with caution like a driver who slows down on a curvy road.